RHBDD3 Antibody | 5529

RHBDD3 Antibody | 5529 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: RHBDD3 antibody was raised against a 13 amino acid synthetic peptide from near the center of human RHBDD3.
The immunogen is located within amino acids 170 - 220 of RHBDD3.

Research Area: Apoptosis

Tested Application: E, WB, IF

Application: RHBDD3 antibody can be used for detection of RHBDD3 by Western blot at 1 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1462 - Rat Lung Tissue Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: RHBDD3 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: RHBDD3 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: RHBDD3 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: RHBDD3 Antibody: PTAG, C22orf3, HS984G1A, Rhomboid domain-containing protein 3

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: RHBDD3 Antibody: The Rhomboid family of proteins is made up of several widely conserved polytopic membrane serine proteases that play roles in growth and development. RHBDD3 was initially identified as a novel pituitary tumor apoptosis gene (PTAG) whose expression was reduced in certain pituitary adenomas. Overexpression of RHBDD3 in AtT20 cells showed an increase in apoptotic activity and caspase activation in response to bromocriptine, and apoptosis-inducing dopamine D2 analog, suggesting that reactivation of RHBDD3 in tumors may be a therapeutically useful tool. Later experiments also showed that RHBDD3 expression is also reduced in several primary colorectal tumors, indicating that loss of RHBDD3 contributes to a blunted apoptotic response and probably predisposes cells towards malignant transformation.